

DAFTAR PUSTAKA

1. Londero SC, Mathiesen JS, Krogdahl A, Bastholt L, Overgaard J, Bentsen J, et al. Completeness and validity in a national clinical thyroid cancer database: DATHYRCA. *Cancer Epidemiol.* 2014;38(5):633–7.
2. Aarestrup J, Kitahara CM, Baker JL. Birthweight and risk of thyroid cancer and its histological types: A large cohort study. *Cancer Epidemiol.* 2019;62(July):101564.
3. Rossi ED, Pantanowitz L, Hornick JL. A worldwide journey of thyroid cancer incidence centred on tumour histology. *Lancet Diabetes Endocrinol.* 2021;9(4):193–4.
4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68(6):394–424.
5. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021;71(3):209–49.
6. Population I, Population M, Sum P. International Agency for Research on Cancer. *WHO Chron.* 1969;23(7):323–6.
7. World Health Organization. Indonesia Source GLOBOCAN 2018. *Int Agency Res Cancer.* 2019;256:1–2.
8. Globocan. Cancer Incident in Indonesia. Vol. 858, International Agency for Research on Cancer. 2020: 1–2.
9. Kementerian Kesehatan R. Beban Kanker di Indonesia. Pusat Data Dan Informasi Kesehatan Kementerian Kesehatan RI. 2019. 1–16.
10. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid.* 2016;26(1):1–133.
11. Schmidbauer B, Menhart K, Hellwig D, Grosse J. Differentiated thyroid cancer—treatment: State of the art. *Int J Mol Sci.* 2017;18(6):1–17.
12. Seidlin S, Marinelli L, Oshry E. Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. *JAMA.* 1946;132:838–47.

13. Andresen NS, Buatti JM, Tewfik HH, Pagedar NA, Anderson CM, Watkins JM. Radioiodine Ablation following Thyroidectomy for Differentiated Thyroid Cancer: Literature Review of Utility, Dose, and Toxicity . *Eur Thyroid J*. 2017;6(4):187–96.
14. Desen W, editor. *Buku Ajar Onkologi Klinis Editor Utana Wan Desen Penerjemah Willie Japaries Balai Penerbit FK UI, Jakarta Ed.2 Page 287.pdf*. 2011th ed. Jakarta: Balai Penerbit FK UI; 2011. 286–289 p.
15. Shah JP. Thyroid Carcinoma: Epidemiology, histology, and diagnosis. *Clin Adv Hematol Oncol*. 2015;13(4):3–6.
16. Oktahermoniza O, Harahap WA, Tofriza T, Rasyid R. Analisis Ketahanan Hidup Lima Tahun Kanker Tiroid yang Dikelola di RSUP Dr. M. Djamil Padang. *J Kesehat Andalas*. 2013;2(3):151.
17. Nixon IJ, Shah JP, Zafereo M, Simo RS, Hay ID, Suárez C, et al. The role of radioactive iodine in the management of patients with differentiated thyroid cancer – An oncologic surgical perspective. *Eur J Surg Oncol*. 2020;46(5):754–62.
18. Hay ID, Johnson TR, Kaggal S, Reinalda MS, Iniguez-Ariza NM, Grant CS, et al. Papillary Thyroid Carcinoma (PTC) in Children and Adults: Comparison of Initial Presentation and Long-Term Postoperative Outcome in 4432 Patients Consecutively Treated at the Mayo Clinic During Eight Decades (1936–2015). *World J Surg*. 2018;42(2):329–42.
19. Mohammad M, Ms A, Mudalal M, Bakry A, Arzeqat T. The Radioactive Iodine (I-131) Efficiency for the Treatment of Well-Differentiated Thyroid Cancer. *HSA J Nucl Med Radiol Radiat Ther*. 2020;5(25):5–10.
20. He Y, Pan MZ, Huang JM, Xie P, Zhang F, Wei LG. Iodine-131: An effective method for treating lymph node metastases of differentiated thyroid cancer. *Med Sci Monit*. 2016;22:4924–8.
21. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. *J Clin Endocrinol Metab*. 2006;91(8):2892–9.
22. Manzil FFP, Kaur H. Radioactive Iodine For Thyroid Malignancies. *StatPearls*. 2022;131.
23. Ravera S, Neyra A., Ferrandino G, Amzel LM, Carrasco N. The Sodium/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications. *Physiol Behav*. 2019;176(3):139–48.
24. V P, G J, J.M B, J.E D, J VS. *Comprehensive Handbook of Iodine: Nutritional, Biochemical, Pathological and Therapeutic Aspects*. In: *Comprehensive Handbook of Iodine: Nutritional, Biochemical, Pathological and Therapeutic Aspects*. Elsevier; 2009. p. 303–14.
25. Aceves C, Mendieta I, Anguiano B, Delgado-González E. Molecular iodine

- has extrathyroidal effects as an antioxidant, differentiator, and immunomodulator. *Int J Mol Sci.* 2021;22(3):1–15.
26. Jang DG. Therapeutic radionuclides: Beta radiation range. *J Instrum.* 2020;15(8).
 27. The Centers for Disease Control and Prevention (CDC). Radioisotope Brief: Iodine-131 (I-131). *Radiat Emergencies.* 2018;131:12–3.
 28. Silberstein EB, Alavi A, Balon HR, Clarke SEM, Divgi C, Gelfand MJ, et al. The SNMMI practice guideline for therapy of thyroid disease with ¹³¹I 3.0. *J Nucl Med.* 2012;53(10):1633–51.
 29. Abidin Z. *Nuklir dan Aplikasinya.* Yogyakarta: Sekolah Tinggi Teknologi Nuklir BATAN; 2022.
 30. Russo D, Scipioni A, Durante C, Ferretti E, Gandini L, Maggisano V, et al. Expression and localization of the sodium/iodide symporter (NIS) in testicular cells. *Endocrine.* 2011;40(1):35–40.
 31. Canale D, Ceccarelli C, Caglieresi C, Moscatelli A, Gavioli S, Santini P, et al. Effects of radioiodine treatment for differentiated thyroid cancer on testis function. *Clin Endocrinol (Oxf).* 2015;82(2):295–9.
 32. Sioka C, Fotopoulos A. Effects of I-131 therapy on gonads and pregnancy outcome in patients with thyroid cancer. *Fertil Steril.* 2011;95(5):1552–9.
 33. van Velsen EFS, Leung AM, Korevaar TIM. Diagnostic and Treatment Considerations for Thyroid Cancer in Women of Reproductive Age and the Perinatal Period. *Endocrinol Metab Clin North Am.* 2022;51(2):403–16.
 34. Suteau V, Munier M, Briet C, Rodien P. Sex bias in differentiated thyroid cancer. *Int J Mol Sci.* 2021;22(23):1–17.
 35. Harahap RA, Pohan PU, Sufitni S. Characteristics of Thyroid Cancer Patients in Haji Adam Malik General Hospital. *Indones J Cancer.* 2021;15(3):112.
 36. Siregar KB, Harahap A., Anas M. *Kanker Tiroid.* Medan: USU press; 2023. 1–48 p.
 37. Miranda-Filho A, Lortet-Tieulent J, Bray F, Cao B, Franceschi S, Vaccarella S, et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. *Lancet Diabetes Endocrinol.* 2021;9(4):225–34.
 38. Bauer AJ. Follicular Thyroid Cancer. *Thyroid Cancer.* 2020;543–4.
 39. Master SR, Burns B. *Medullary Thyroid Cancer Pathophysiology Histopathology.* StatPearls Publishing; 2023.
 40. Limaiem F, Kashyap S, Naing PT, Giwa AO. *Anaplastic thyroid cancer.* StatPearls Publishing. StatPearls Publishing; 2023.
 41. Sorrenti S, Baldini E, Pironi D, Lauro A, D’Orazi V, Tartaglia F, et al. *Iodine : Its Role in Thyroid Hormone Biosynthesis and Beyond.* 2021;

42. Darrouzet E, Lindenthal S, Marcellin D, Pellequer JL, Pourcher T. The sodium/iodide symporter: State of the art of its molecular characterization. *Biochim Biophys Acta - Biomembr.* 2014;1838(1 PARTB):244–53.
43. Chung HR. Iodine and thyroid function. *Ann Pediatr Endocrinol Metab.* 2014;19(1):8.
44. De La Vieja A, Santisteban P. Role of iodide metabolism in physiology and cancer. *Endocr Relat Cancer.* 2018;25(4):R225–45.
45. C Arthur G, Hall J. *Guyton and Hall textbook of medical physiology.* United States of America: Elsevier; 2012.
46. Pirahanchi Y, Toro F, Jialal I. Physiology, Thyroid Stimulating Hormone. *StatPearls.* 2020;1–5.
47. Liu YC, Yeh CT, Lin KH. Molecular functions of thyroid hormone Signaling in regulation of cancer progression and anti-apoptosis. *Int J Mol Sci.* 2020;21(9):1–27.
48. Nava-Villalba M, Nuñez-Anita RE, Bontempo A, Aceves C. Activation of peroxisome proliferator-activated receptor gamma is crucial for antitumoral effects of 6-iodolactone. *Mol Cancer.* 2015;14(1):1–11.
49. Zhang D, Xu X, Li J, Yang X, Sun J, Wu Y, et al. High iodine effects on the proliferation, apoptosis, and migration of papillary thyroid carcinoma cells as a result of autophagy induced by BRAF kinase. *Biomed Pharmacother.* 2019;120(May):109476.
50. Djoko Rianto BU, Wibowo AS, Herdini C. The difference in thyroid stimulating hormone levels between differentiated carcinoma and benign enlargement. *Int Arch Otorhinolaryngol.* 2020;24(1):E73–9.
51. Mutohar A, Setiabudi W, Shintawati R. Laju paparan dan dosis radiasi dari pasien terapi kelainan kelenjar tiroid dengan pemberian radiofarmaka Iodium-131. *Youngster Phys J.* 2017;6(1):22–31.
52. Michael Tuttle R, Ahuja S, Avram AM, Bernet VJ, Bourguet P, Daniels GH, et al. Controversies, Consensus, and Collaboration in the Use of 131I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular I. Vol. 29, *Thyroid.* 2019. 461–470 p.
53. Araque KA, Gubbi S, Klubo-Gwiedzinska J. Updates on the management of thyroid cancer. *Horm Metab Res.* 2020;52(8):562–77.
54. Bolus NE. Basic review of radiation biology and terminology. *J Nucl Med Technol.* 2017;45(4):259–64.
55. Carante MP, Ramos RL, Ballarini F. Radiation Damage in Biomolecules and Cells 2.0. *Int J Mol Sci.* 2023;24(4):25–7.
56. Rydberg B. Radiation-induced DNA damage and chromatin structure. *Acta*

- Oncol (Madr). 2001;40(6):682–5.
57. Mercadante AA, Kasi A. Genetics, Cancer Cell Cycle Phases. *StatPearls*. 2021;7–9.
 58. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. *Int J Radiat Oncol Biol Phys*. 2004;59(4):928–42.
 59. Elliyanti A. Molecular Radiobiology and Radionuclides Therapy Concepts. In: Jekunen A, editor. *The Evolution of Radionanotargeting Towards Clinical Precision Oncology: a Festschrift in Honor of Kalevi Kairemo*. Finland: Bentham Books; 2022.395–408.
 60. Jelonek K, Widlak P, Pietrowska M. The Influence of Ionizing Radiation on Exosome Composition, Secretion and Intercellular Communication. *Protein Pept Lett*. 2016;23(7):656–63.
 61. Dagueneat E, Louati S, Wozny AS, Vial N, Gras M, Guy JB, et al. Radiation-induced bystander and abscopal effects: important lessons from preclinical models. *Br J Cancer*. 2020;123(3):339–48.
 62. Farias V de A, Tovar I, del Moral R, O'Valle F, Expósito J, Oliver FJ, et al. Enhancing the Bystander and Abscopal Effects to Improve Radiotherapy Outcomes. *Front Oncol*. 2020;9(January):1–14.
 63. Kumar C, Shetake N, Desai S, Kumar A, Samuel G, Pandey BN. Relevance of radiobiological concepts in radionuclide therapy of cancer. *Int J Radiat Biol*. 2016;92(4):173–86.
 64. Albano D, Bertagna F, Panarotto MB, Giubbini R. Early and late adverse effects of radioiodine for pediatric differentiated thyroid cancer. *Pediatr Blood Cancer*. 2017;64(11).
 65. Riesco-Eizaguirre G, Leoni SG, Mendiola M, Estevez-Cebrero MA, Gallego MI, Redondo A, et al. NIS mediates iodide uptake in the female reproductive tract and is a poor prognostic factor in ovarian cancer. *J Clin Endocrinol Metab*. 2014;99(7):1199–208.
 66. Piek MW, Postma EL, Van Leeuwen R, De Boer JP, Bos AME, Lok C, et al. The Effect of Radioactive Iodine Therapy on Ovarian Function and Fertility in Female Thyroid Cancer Patients: A Systematic Review and Meta-Analysis. *Thyroid*. 2021;31(4):658–68.
 67. Busnelli A, Vitagliano A, Mensi L, Acerboni S, Bulfoni A, Filippi F, et al. Fertility in female cancer survivors: a systematic review and meta-analysis. *Reprod Biomed Online*. 2020;41(1):96–112.
 68. Wu JX, Young S, Ro K, Li N, Leung AM, Chiu HK, et al. Reproductive outcomes and nononcologic complications after radioactive iodine ablation for well-differentiated thyroid cancer. *Thyroid*. 2015;25(1):133–8.
 69. Chaffin CL, Vandervoort CA. Follicle growth, ovulation, and luteal formation in primates and rodents: A comparative perspective. *Exp Biol Med*. 2013;238(5):539–48.

70. Acibucu F, Acibucu DO, Akkar B, Dokmetas HS. Evaluation of Ovarian Reserve with AMH Level in Patients with Well-Differentiated Thyroid Cancer Receiving Radioactive Iodine Ablation Treatment. *Exp Clin Endocrinol Diabetes*. 2016;124(10):593–6.
71. Yaish I, Azem F, Gutfeld O, Silman Z, Serebro M, Sharon O, et al. A Single Radioactive Iodine Treatment Has a Deleterious Effect on Ovarian Reserve in Women with Thyroid Cancer: Results of a Prospective Pilot Study. *Thyroid*. 2018;28(4):522–7.
72. Karaca T, Demirtas S, Uzun Goren D. Pendrin and sodium/iodide symporter protein expression in the testicular tissue of normal and diabetic rats in prepubertal and post pubertal stages. *Iran J Vet Res*. 2018;19(4):255–61.
73. Cai Y, Cai Y. The effect of radioactive iodine treatment for differentiated thyroid cancer on male gonadal function : a meta-analysis.
74. Rosário PWS, Barroso ÁL, Rezende LL, Padrão EL, Borges MAR, Guimarães VC, et al. Testicular function after radioiodine therapy in patients with thyroid cancer. *Thyroid*. 2006;16(7):667–70.
75. Moolhuijsen LME, Visser JA. Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function. *J Clin Endocrinol Metab*. 2020;105(11):3361–73.
76. Kurniawan LB. Peran Anti-Mullerian Hormone pada Penilaian Kapasitas Reproduksi Wanita. *J CDK*. 2017;44(5):319–22.
77. Mishra B, Ripperdan R, Ortiz L, Luderer U. Very low doses of heavy oxygen ion radiation induce premature ovarian failure. *Reproduction*. 2017;154(2):123–33.
78. Deadmond A, Koch CA. Ovarian Reserve Testing. *Clin Reprod Med Surg A Pract Guid Fourth Ed*. 2022;(2):323–33.
79. Adamska A, Tomczuk-Bobik P, Popławska-Kita AB, Siewko K, Buczyńska A, Szumowski P, et al. Assessment of different markers of ovarian reserve in women with papillary thyroid cancer treated with radioactive iodine. *Endocr Connect*. 2021;10(10):1283–90.
80. Hosseini A, Lavasani Z. The effect of radioactive iodine therapy on anti-Müllerian hormone changes in women with thyroid cancer at reproductive age: a prospective study. *Middle East Fertil Soc J*. 2023;28(1):24–8.
81. Evranos B, Faki S, Polat SB, Bestepe N, Ersoy R, Cakir B. Effects of Radioactive Iodine Therapy on Ovarian Reserve: A Prospective Pilot Study. *Thyroid*. 2018;28(12):1702–7.
82. Van Velsen EFS, Visser WE, Van Den Berg SAA, Kam BLR, Van Ginhoven TM, Massolt ET, et al. Longitudinal Analysis of the Effect of Radioiodine Therapy on Ovarian Reserve in Females with Differentiated Thyroid Cancer. *Thyroid*. 2020;30(4):580–7.
83. Nies M, Cantineau AEP, Arts EGJM, Van Den Berg MH, Van Leeuwen FE,

- Muller Kobold AC, et al. Long-term effects of radioiodine treatment on female fertility in survivors of childhood differentiated thyroid carcinoma. *Thyroid*. 2020;30(8):1169–76.
84. Mittica M, Dotto A, Comina M, Teliti M, Monti E, Giusti M. Cross-sectional and prospective study on anti-Müllerian hormone changes in a cohort of premenopausal women with a history of differentiated thyroid cancer. *Thyroid Res*. 2020;13(1):1–9.
 85. Giusti M, Mittica M, Comite P, Campana C, Gay S, Mussap M. Anti-Müllerian hormone in premenopausal females after ablative radioiodine treatment for differentiated thyroid cancer. *Endocrine*. 2018;60(3):516–23.
 86. Decanter C, Cloquet M, Dassonneville A, Orazio ED, Mailliez A, Pigny P. Different patterns of ovarian recovery after cancer treatment suggest various individual ovarian susceptibilities to chemotherapy. *Reprod Biomed Online*. 2018;36(6):711–8.
 87. Orłowski M, Sarao MS. Physiology, Follicle Stimulating Hormone. *StatPearls*. 2019;1–5.
 88. Raju GAR, Chavan R, Deenadayal M, Gunasheela D, Gutgutia R, HariPriya G, et al. Luteinizing hormone and follicle stimulating hormone synergy: A review of role in controlled ovarian hyper-stimulation. *J Hum Reprod Sci*. 2013;6(4):227–34.
 89. La Marca A, Argento C, Sighinolfi G, Grisendi V, Carbone M, D'Ippolito G, et al. Possibilities and Limits of Ovarian Reserve Testing in ART. *Curr Pharm Biotechnol*. 2012;13(3):398–408.
 90. Arslan AA, Zeleniuch-Jacquotte A, Lukanova A, Rinaldi S, Kaaks R, Toniolo P. Reliability of follicle-stimulating hormone measurements in serum. *Reprod Biol Endocrinol*. 2003;1:1–5.
 91. Kelsey TW, Hua CH, Wyatt A, Indelicato D, Wallace WH. A predictive model of the effect of therapeutic radiation on the human ovary. *PLoS One*. 2022;17(11 November):1–15.
 92. Reed BG, Carr BR. *The Normal Menstrual Cycle and the Control of Ovulation*. Endotext. 2000;1–14.
 93. Jacobson, Melanie H, Mertens, Ann C, Spencer, Jeessica B, Manatunga, Amita K., Howards PP. Menses resumption after cancer treatment-induced amenorrhea occurs early or not at all. *Fertil Steril*. 2017;46(2):248–56.
 94. Ko KY, Yen RF, Lin CL, Cheng MF, Huang WS, Kao CH. Pregnancy outcome after I-131 therapy for patients with thyroid cancer a nationwide population-based cohort study. *Med (United States)*. 2016;95(5):1–6.
 95. Kim HO, Lee K, Lee SM, Seo GH. Association between Pregnancy Outcomes and Radioactive Iodine Treatment after Thyroidectomy among Women with Thyroid Cancer. *JAMA Intern Med*. 2020;180(1):54–61.
 96. Zhang L, Huang Y, Zheng Y, Cai L, Wen J, Chen G. The effect of I-131

therapy on pregnancy outcomes after thyroidectomy in patients with differentiated thyroid carcinoma: a meta-analysis. *Endocrine*. 2021;73(2):301–7.

97. Lee SY. No Increased Risks of Abortion, Preterm Delivery, or Congenital Malformation at 6 Months After Radioactive Iodine Treatment for Thyroid Cancer. *Clin Thyroidol*. 2019;31(12):533–6.
98. Moon S, Yi KH, Park YJ. Risk of Adverse Pregnancy Outcomes in Young Women with Thyroid Cancer: A Systematic Review and Meta-Analysis. *Cancers (Basel)*. 2022;14(10):1–16.
99. Anderson, Chelsea, Engel, Stephanie M, Weaver, Mark A, Zevallos, Jose P., Nichols Hazel B. Birth rates after radioactive iodine treatment for differentiated thyroid cancer. *Int J Cancer*. 2017;19–20(11):2291–2295.
100. Cao Q, Zhu H, Zhang J, Li Y, Huang W. Pregnancy Outcomes in Thyroid Cancer Survivors: A Propensity Score-Matched Cohort Study. *Front Endocrinol (Lausanne)*. 2022;13(February):1–9.
101. Qu N, Itoh M, Sakabe K. Effects of chemotherapy and radiotherapy on spermatogenesis: The role of testicular immunology. *Int J Mol Sci*. 2019;20(4).
102. Oduwole OO, Peltoketo H, Huhtaniemi IT. Role of follicle-stimulating hormone in spermatogenesis. *Front Endocrinol (Lausanne)*. 2018;9(December):1–11.
103. Soltani S, Aghaee A, Zakavi SR, Mottaghi M, Emadzadeh M, Kasaeian Naeini S. Effects of radioiodine therapy on fertility indicators among men with differentiated thyroid cancer: A cohort study. *Int J Reprod Biomed*. 2023;21(5):387–94.
104. Bourcigaux N, Rubino C, Berthaud I, Toubert ME, Donadille B, Leenhardt L, et al. Impact on testicular function of a single ablative activity of 3.7 GBq radioactive iodine for differentiated thyroid carcinoma. *Hum Reprod*. 2018;33(8):1408–16.
105. Nies M, Arts EGJM, van Velsen EFS, Burgerhof JGM, Muller Kobold AC, Corssmit EPM, et al. Long-term male fertility after treatment with radioactive iodine for differentiated thyroid carcinoma. *Eur J Endocrinol*. 2021;185(6):775–82.
106. Esquerré-Lamare C, Isus F, Moinard N, Bujan L. Sperm DNA fragmentation after radioiodine treatment for differentiated thyroid cancer. *Basic Clin Androl*. 2015;25(1):4–9.
107. Hussain T, Kandeel M, Metwally E, Murtaza G, Kalhor DH, Yin Y, et al. Unraveling the harmful effect of oxidative stress on male fertility: A mechanistic insight. *Front Endocrinol (Lausanne)*. 2023;14(February):1-13.